Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination

Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021

(2022) Georgina Ireland et al.   Eurosurveillance

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

(2022) Sue Ann Costa Clemens et al.   LANCET

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

(2022) Yunlong Cao et al.   NATURE

Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine

(2022) Sitthichai Kanokudom et al.   Vaccines

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

(2021) Piyada Supasa et al.   CELL

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

(2021) Wilfredo F. Garcia-Beltran et al.   CELL

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

(2021) Pengfei Wang et al.   NATURE

Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination

(2021) Rishi R. Goel et al.   Science Immunology

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

(2021) Chang Liu et al.   CELL

T cell immune responses to SARS-CoV-2 and variants of concern (Alpha and Delta) in infected and vaccinated individuals

(2021) Stanley C. Jordan et al.   Cellular & Molecular Immunology

SARS-CoV-2-specific T cells in infection and vaccination

(2021) Antonio Bertoletti et al.   Cellular & Molecular Immunology

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

(2021) Xinxue Liu et al.   LANCET

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

(2021) Mine Durusu Tanriover et al.   LANCET

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

(2021) Zijun Wang et al.   NATURE

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile

(2021) Alejandro Jara et al.   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees

(2021) Daryl Geers et al.   Science Immunology

Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study

(2021) William M Souza et al.   Lancet Microbe

Structural and functional insights into the spike protein mutations of emerging SARS-CoV-2 variants

(2021) Deepali Gupta et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Characterization of the novel SARS‐CoV‐2 Omicron (B.1.1.529) variant of concern and its global perspective

(2021) Shailendra K. Saxena et al.   JOURNAL OF MEDICAL VIROLOGY

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

(2021) Alasdair P S Munro et al.   LANCET

CoronaVac induces lower neutralising activity against variants of concern than natural infection

(2021) Vimvara Vacharathit et al.   LANCET INFECTIOUS DISEASES

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials

(2021) Gang Zeng et al.   LANCET INFECTIOUS DISEASES

China’s COVID vaccines have been crucial — now immunity is waning

(2021) Smriti Mallapaty   NATURE

Waning Immunity after the BNT162b2 Vaccine in Israel

(2021) Yair Goldberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection

(2021) Ital Nemet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost

(2021) Jingwen Ai et al.   Emerging Microbes & Infections

The Global Epidemic of the SARS-CoV-2 Delta Variant, Key Spike Mutations and Immune Escape

(2021) Dandan Tian et al.   Frontiers in Immunology

Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2

(2020) Hui Wang et al.   CELL

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

(2020) Pedro M Folegatti et al.   LANCET

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

(2020) Lisa A. Jackson et al.   NEW ENGLAND JOURNAL OF MEDICINE